AI
PRVB

Atom Investors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Atom Investors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-42,680
Closed -$312K – 330
2022
Q1 		$312K Buy
+42,680
New +$255K 0.15% 133

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Atom Investors's PRVB Position: Q2 2022 in Review

Atom Investors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2022, closing a stake of 42,680 shares — an estimated $312K sold.

Atom Investors first reported a position in PRVB in Q1 2022 and held it in 1 quarter. The position peaked at $312K in Q1 2022. 115 funds tracked by Wall St. Rank hold PRVB as of Q2 2022.

  • Atom Investors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Atom Investors sold 42,680 Provention Bio, Inc. Common Stock shares in Q2 2022, an estimated $312K.
  • Atom Investors first reported a position in Provention Bio, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Atom Investors's Provention Bio, Inc. Common Stock position peaked at $312K in Q1 2022.
  • 115 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2022.

Based on Atom Investors's 13F filing for Q2 2022, filed 15 Aug 2022.